Explore Rezdiffra (resmetirom), an approved MASH treatment, and Efruxifermin (EFX), an investigational therapy. Understand their mechanisms and potential impact on metabolic dysfunction-associated steatohepatitis.

Rezdiffra and Efruxifermin: Key Developments in MASH Treatment

Metabolic Dysfunction-Associated Steatohepatitis (MASH